Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
363.20B
Market cap363.20B
Price-Earnings ratio
112.64
Price-Earnings ratio112.64
Dividend yield
2.41%
Dividend yield2.41%
Average volume
11.23M
Average volume11.23M
High today
$149.24
High today$149.24
Low today
$143.31
Low today$143.31
Open price
$144.35
Open price$144.35
Volume
5.86M
Volume5.86M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$82.01
52 Week low$82.01

Stock Snapshot

With a market cap of 363.2B, Merck(MRK) trades at $147.25. The stock has a price-to-earnings ratio of 112.64 and currently yields dividends of 2.41%.

On 2026-10-29, Merck(MRK) stock traded between a low of $143.31 and a high of $149.24. Shares are currently priced at $147.25, which is +2.8% above the low and -1.3% below the high.

Merck(MRK) shares are trading with a volume of 5.86M, against a daily average of 11.23M.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

MRK News

Bloomberg 60m
Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue - Bloomberg.com

...

Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue - Bloomberg.com
24/7 Wall St. 3h
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher

Investing Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher Merck (NYSE:MRK | MRK Price Prediction) is t...

Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
TipRanks 5h
Merck Stock Rises 2% on $830 Million Keytruda Sales Beat Q3 Forecasts and Higher Full-Year Profit Outlook

Merck & Co (MRK) shares rose 2.14% in Thursday premarket trading after the drugmaker beat third-quarter Wall Street estimates and raised its full-year adjusted...

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

The Wall Street Journal 7h
Merck Revenue Up on Keytruda, Winrevair Growth

Merck & Co. reported higher revenue in the latest quarter. Ralph Orlowski / REUTERS Merck MRK -0.63 %decrease; down pointing triangle & Co. reported higher rev...

Merck Revenue Up on Keytruda, Winrevair Growth
CNBC 7h
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength

The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024. Merck on Thursday topped third-quarter estimates and hiked its...

Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Seeking Alpha 1d
Pharma giants Merck, Eli Lilly face earnings health check

Pharmaceutical giants Merck (MRK) and Eli Lilly (LLY) are scheduled to report third-quarter results on October 29, with analysts expecting a year-on-year earnin...

Pharma giants Merck, Eli Lilly face earnings health check
Zacks 1d
Brokers Suggest Investing in Merck: Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brok...

Brokers Suggest Investing in Merck: Read This Before Placing a Bet
Simply Wall St 2d
Could Merck Reset Endometrial Cancer Care With Two Phase 3 Wins?

Merck (NYSE:MRK) reported new Phase 3 data for sacituzumab tirumotecan and KEYTRUDA in advanced or recurrent endometrial cancer, highlighted at a major oncology...

Benzinga 3d
Merck Endometrial Cancer Studies Show Significant Survival Gains

Merck & Co. Inc. (NYSE:MRK) on Monday announced results from two late-stage clinical studies evaluating treatments for advanced or recurrent endometrial cancer...

Merck Endometrial Cancer Studies Show Significant Survival Gains
Zacks 3d
Countdown to Merck Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

The upcoming report from Merck (MRK Quick QuoteMRK - Free Report) is expected to reveal quarterly earnings of $2.12 per share, indicating a decline of 17...

Countdown to Merck Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.